ReviewClinical immunology (Orlando, Fla.)2012
Autoantibody stabilization of the classical pathway C3 convertase leading to C3 deficiency and Neisserial sepsis: C4 nephritic factor revisited.
Review in Clinical immunology (Orlando, Fla.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04295733 (Evaluation of Safety, Tolerability and Immunogenicity of Two Doses of the 4CMenB Vaccine in Adults With an Immunodeficiency), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Safety, Tolerability and Immunogenicity of Two Doses of the 4CMenB Vaccine in Adults With an Immunodeficiency
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- Complements and Their Role in Systemic Disorders.Cureus · 2024Review
- The complement system and human autoimmune diseases.Journal of autoimmunity · 2023Review
- Challenges in diagnostic testing of nephritic factors.Frontiers in immunology · 2022Review
- Serum C1q Levels Have Prognostic Value for Sepsis and are Related to the Severity of Sepsis and Organ Damage.Journal of inflammation research · 2021Article
- Different Aspects of Classical Pathway Overactivation in Patients With C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis.Frontiers in immunology · 2021Article
- Complement C4, Infections, and Autoimmune Diseases.Frontiers in immunology · 2021Review
- The Immunopathology of Complement Proteins and Innate Immunity in Autoimmune Disease.Clinical reviews in allergy & immunology · 2020Review
- C4 nephritic factor in patients with immune-complex-mediated membranoproliferative glomerulonephritis and C3-glomerulopathy.Orphanet journal of rare diseases · 2019Article
- Nephritic Factors: An Overview of Classification, Diagnostic Tools and Clinical Associations.Frontiers in immunology · 2019Review
- Factor B and C4b2a Autoantibodies in C3 Glomerulopathy.Frontiers in immunology · 2019Review
- C4 Nephritic Factors in C3 Glomerulopathy: A Case Series.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2017Article
- Testing the Activity of Complement Convertases in Serum/Plasma for Diagnosis of C4NeF-Mediated C3 Glomerulonephritis.Journal of clinical immunology · 2016Article
- Meningococcal Vaccinations.Infectious diseases and therapy · 2016Review
- Early Components of the Complement Classical Activation Pathway in Human Systemic Autoimmune Diseases.Frontiers in immunology · 2016Review
- Complement-related proteins control the flavivirus infection of Aedes aegypti by inducing antimicrobial peptides.PLoS pathogens · 2014Article
- Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation.Immunity · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
C3 deficiency is a rare disorder that leads to recurrent pyogenic infections. Here we describe a previously healthy 18 y/o Caucasian male with severe meningococcal disease. Total hemolytic activity was zero secondary to an undetectable C3. The C3 gene was normal by sequencing. Mixing the patient's serum with normal human serum led to C3 consumption. An IgG autoantibody in the patient's serum was identified that stabilized the classical pathway C3 and C5 convertases, thus preventing decay of these enzyme complexes. This autoantibody is an example of a C4 nephritic factor, with an additional feature of stabilizing the C5 convertase. Previous patients with C4 nephritic factor had membranoproliferative glomerulonephritis. Two years after presentation, this patient's C3 remains undetectable with no evidence of renal disease. We revisit the role of autoantibodies to classical pathway convertases in disease, review the literature on C4-NeF and comment on its detection in the clinical laboratory.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.